Early Conversion From Tacrolimus to Efalizumab Maintenance Therapy in Kidney Transplant Recipients

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

April 30, 2009

Study Completion Date

April 30, 2009

Conditions
Kidney TransplantationChronic Kidney Failure
Interventions
DRUG

efalizumab

Administration of a test dose of efalizumab 0.7mg/kg will be administered at enrollment. Weekly subcutaneous injections of efalizumab 1mg/kg will begin with study visit 2 and continue for 1 year for this pilot study.

Trial Locations (1)

30322

Emory University, Atlanta

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Emory University

OTHER